Blood Cancer Talks

Nov 13 2024 54 ep. 51 mins 16
Blood Cancer Talks Podcast artwork

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

  Education  Health & Fitness
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

Nov 13 2024 44 mins  
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubme

Episode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew Evens

Oct 26 2024 42 mins  
In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/3. Sequential BV-AVD in older adul

Episode 51. Venetoclax in AML with Dr. Andrew Wei

Sep 27 2024 56 mins  
In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa20129712. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract3.

Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt

Aug 29 2024 41 mins  
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi

Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

Aug 14 2024 43 mins  
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercepthttps://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr

Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds

Jul 21 2024 57 mins  
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring systemhttps://pubmed.ncbi.nlm.nih.gov/31945802/2. REVEAL studyhttps://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell3. MAJIC PV studyhttps://ascopubs.org

Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

Jul 06 2024 47 mins  
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCLhttps://library.ehaweb.org/eha/2024/eha2024-congre

Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin

Jun 09 2024 57 mins  
In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:1. Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL02. E

Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

May 29 2024 60 mins  
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced Internation

Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

May 01 2024 52 mins  
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed:1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs obser